전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
major or clinically relevant non- major bleeding
hemorragia mayor o no mayor clínicamente relevante
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
clinically relevant non-major
hemorragia no mayor clínicamente relevante
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
non-major clinically relevant bleeding events
hemorragia no mayor clínicamente relevante
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
major and non-major clinically relevant bleeding events
hemorragia mayor y no mayor clínicamente relevante
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the primary safety endpoint was clinically relevant bleeding (major or clinically relevant non-major).
la variable principal de seguridad fue el sangrado clínicamente relevante (mayor o no mayor clínicamente relevante).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
major bleeding events/clinically relevant bleeds
episodios de sangrado mayor/sangrados clínicamente relevantes
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
clinically relevant non major bleeding occurred in 5 (0.3%) fondaparinux patients and 8 (0.5%) placebo patients.
el sangrado no mayor clínicamente relevante tuvo lugar en 5 (0,3%) pacientes con fondaparinux y 8 (0,5%) pacientes con placebo.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.
la variable secundaria de seguridad (hemorragia mayor o no mayor clínicamente relevante) mostró unas tasas más altas en los pacientes tratados con rivaroxaban 20 mg una vez al día, en comparación con placebo.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
r there is no pharmacodynamic or clinically relevant pharmacokinetic interaction with low-dose
en individuos sanos, no hay interacción farmacodinámica o farmacocinética clínicamente relevante me
마지막 업데이트: 2008-03-04
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
no statistically significant or clinically relevant effects were found for acupuncture compared to sham acupuncture.
no se encontraron efectos estadísticamente significativos o clínicamente relevantes para la acupuntura comparada con la acupuntura simulada.
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
in the pooled studies the primary safety endpoints of major bleeding, major or clinically relevant bleeding and any bleeding were significantly lower than warfarin at a nominal alpha level of 5 %.
en los estudios agrupados, las variables principales de seguridad de sangrado mayor, sangrado mayor o clínicamente relevante y cualquier sangrado fueron significativamente menores que con warfarina a un valor nominal alfa del 5 %.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
a on-treatment period: time from first dose of study drug to last dose plus 3 days. b primary safety endpoint: clinically relevant bleeding (composite of major and clinically relevant non-major bleeding).
a periodo en tratamiento: tiempo desde la primera dosis del medicamento del estudio hasta la última dosis más 3 días. b variable principal de seguridad: sangrado clínicamente relevante (compuesto de sangrado mayor y sangrado no mayor clínicamente relevante).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
oral contraceptives there is no pharmacodynamic or clinically relevant pharmacokinetic interaction with low-dose triphasic oral contraceptives in healthy subjects.
anticonceptivos orales en individuos sanos, no hay interacción farmacodinámica o farmacocinética clínicamente relevante con anticonceptivos orales trifásicos de dosis baja.
마지막 업데이트: 2012-04-10
사용 빈도: 3
품질:
the safety endpoints of major bleeding, the composite of major and clinically relevant non-major (crnm) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see table 5).
las variables de seguridad de sangrado mayor, compuesta por sangrado mayor y sangrado no mayor clínicamente relevante (nmcr), y de todos los sangrados mostraron tasas similares para los pacientes tratados con 2,5 mg de apixaban en comparación con pacientes tratados con 40 mg de enoxaparina (ver tabla 5).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in a multiple dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed.
en un ensayo clínico con dosis múltiple, en el cual se administraron hasta 20 mg de desloratadina al día durante 14 días, no se observaron efectos cardiovasculares estadística o clínicamente relevantes.
마지막 업데이트: 2017-04-26
사용 빈도: 18
품질:
in a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was
en un ensayo clínico con dosis múltiple, en adultos y adolescentes, en el cual se administraron hasta 20 mg de desloratadina al día durante 14 días, no se observaron efectos cardiovasculares estadística o clínicamente relevantes.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
in a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed.
en un ensayo clínico con dosis múltiple, en adultos y adolescentes, en el cual se administraron hasta 20 mg de desloratadina al día durante 14 días, no se observaron efectos cardiovasculares estadística o clínicamente relevantes.
마지막 업데이트: 2017-04-26
사용 빈도: 8
품질:
in a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed.in a clinical pharmacology trial, in adults and adolescents, in which desloratadine was
en un ensayo clínico con dosis múltiple, en adultos y adolescentes, en el cual se administraron hasta 20 mg de desloratadina al día durante 14 días, no se observaron efectos cardiovasculares estadística o clínicamente relevantes.
마지막 업데이트: 2008-03-04
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
based on the results of the qtc study, conducted in healthy subjects at therapeutic and supra-therapeutic doses, it can be concluded that defitelio has no significant or clinically relevant qtc-prolonging potential at doses up to 4 times higher than therapeutically indicated.
en base a los resultados del ensayo sobre el qtc, realizados en pacientes sanos a dosis terapéuticas y supraterapéuticas, puede concluirse que defitelio no presenta un potencial importante ni clínicamente relevante de prolongación del qtc a dosis de hasta 4 veces superiores al nivel terapéutico indicado.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/vka treatment group (11.4% (274/2405)).
las tasas de incidencia de la variable principal de seguridad (eventos hemorrágicos mayores o no mayores clínicamente relevantes) fueron ligeramente inferiores en el grupo de tratamiento con rivaroxaban (10,3% (249/2412)) frente a las del grupo de tratamiento con enoxaparina/avk (11,4% (274 / 2405)).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: